GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
New inhalers would have near-zero Global Warming Potential propellant
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio
Subscribe To Our Newsletter & Stay Updated
